Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07562438 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Name: Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer — clinical trial record (NCT07562438)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorFirst Affiliated Hospital of Fujian Medical University

Started2026-04-29

View on ClinicalTrials.gov ↗

First Affiliated Hospital of Fujian Medical University

56 trials monitored

See all monitored trials

Prostate Cancer

2,471 trials monitored

See 156 trials at risk

PSMA is an ideal target for precision diagnosis and treatment of prostate cancer. P17-088 is a novel albumin-binding PSMA-targeted radioligand. This study aims to explore the safety and efficacy of 177Lu-labeled P17-088 for treating patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

Trial Details

NCT Number	NCT07562438
Lead Sponsor	First Affiliated Hospital of Fujian Medical University
Conditions	Prostate Cancer
Enrollment	20 participants
Start Date	2026-04-29
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-01